{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-071764","form_type":"8-K","ticker":"CVKD","cik":"0001937993","company_name":"Cadrenal Therapeutics, Inc.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.647619+00:00","generated_at":"2026-05-17T21:04:25.245015+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cadrenal to begin tecarfarin trial in ESKD patients transitioning to dialysis later this year","bullets":["Trial includes ESKD patients with and without atrial fibrillation, enrollment planned to begin later this year.","Tecarfarin has orphan drug and fast-track designations for ESKD+AFib, highlighting unmet need.","Addresses critical gap: no proven anticoagulant for dialysis initiation period, which carries excess cardiovascular risk.","CEO Quang X. Pham calls the study an important step forward for tecarfarin development."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-071764","json":"https://secwatch.observer/filing/0001213900-25-071764.json","markdown":"https://secwatch.observer/filing/0001213900-25-071764.md","text":"https://secwatch.observer/filing/0001213900-25-071764.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937993/000121390025071764/0001213900-25-071764-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937993/000121390025071764/ea0251809-8k_cadrenal.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:04:25.245015+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}